| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,630,000 |
| Market
Cap: |
13.95(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$129.52 - $265 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 664 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BeiGene is a commercial-stage biotechnology company focused on developing and commercializing molecularly-targeted and immuno-oncology cancer therapeutics. Co.'s clinical-stage drug candidates include: Zanubrutinib, which is a small molecule inhibitor of Bruton's tyrosine kinase for the treatment of mantle cell lymphoma in adult patients; Tislelizumab, which is a humanized monoclonal antibody against the immune checkpoint receptor programmed cell death protein 1; Pamiparib (BGB-290), which is for the treatment of various solid tumors; and Lifirafenib, which is an investigational small molecule inhibitor with RAF monomer and dimer inhibition activities.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
100,397 |
1,200,397 |
5,371,251 |
5,588,274 |
| Total Sell Value |
$15,909,372 |
$214,459,372 |
$1,041,558,017 |
$1,085,894,829 |
| Total People Sold |
2 |
3 |
8 |
9 |
| Total Sell Transactions |
6 |
7 |
21 |
54 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-03-16 |
4 |
GD |
$0.00 |
$0 |
D/D |
67,444 |
5,445,112 |
|
- |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-03-08 |
4 |
S |
$223.00 |
$15,287,339 |
D/D |
(67,635) |
0 |
|
14% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-03-08 |
4 |
OE |
$0.13 |
$8,793 |
D/D |
67,635 |
67,635 |
|
- |
|
| Wang Julia Aijun |
Chief Financial Officer |
• – – |
2023-03-01 |
4 |
S |
$240.21 |
$82,392 |
D/D |
(343) |
0 |
|
20% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-01-12 |
4 |
AS |
$260.31 |
$1,302,585 |
I/I |
(5,000) |
0 |
|
-9% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-01-11 |
4 |
AS |
$250.39 |
$631,647 |
D/D |
(2,500) |
0 |
|
-5% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2023-01-10 |
4 |
AS |
$246.97 |
$3,378,292 |
I/I |
(13,594) |
0 |
|
-7% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2023-01-10 |
4 |
AS |
$247.00 |
$1,689,157 |
D/D |
(6,797) |
0 |
|
-7% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-01-10 |
4 |
AS |
$250.09 |
$400,152 |
D/D |
(1,600) |
0 |
|
-7% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2023-01-09 |
4 |
AS |
$250.00 |
$225,000 |
D/D |
(900) |
0 |
|
-7% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-29 |
4 |
AS |
$224.42 |
$770,798 |
I/I |
(3,434) |
0 |
|
10% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-29 |
4 |
AS |
$224.42 |
$385,174 |
D/D |
(1,716) |
0 |
|
10% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-28 |
4 |
AS |
$224.73 |
$164,724 |
I/I |
(733) |
0 |
|
12% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-28 |
4 |
AS |
$224.73 |
$82,474 |
D/D |
(367) |
0 |
|
12% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-27 |
4 |
AS |
$224.29 |
$502,193 |
I/I |
(2,239) |
0 |
|
14% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-12-27 |
4 |
AS |
$224.29 |
$251,209 |
D/D |
(1,120) |
0 |
|
14% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2022-12-13 |
4 |
AS |
$210.59 |
$636,723 |
I/I |
(3,013) |
0 |
|
19% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2022-11-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
52,000 |
5,577,556 |
|
- |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-11-15 |
4 |
AS |
$204.24 |
$1,019,229 |
I/I |
(4,928) |
0 |
|
7% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-11-15 |
4 |
AS |
$203.64 |
$5,171,105 |
D/D |
(25,000) |
0 |
|
7% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2022-11-15 |
4 |
AS |
$210.14 |
$417,541 |
I/I |
(1,987) |
0 |
|
7% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-09-21 |
4 |
AS |
$148.25 |
$2,921,714 |
I/I |
(19,480) |
0 |
|
71% |
|
| Oyler John |
Chief Executive Officer |
• • – |
2022-09-20 |
4 |
AS |
$153.32 |
$4,684,842 |
I/I |
(30,520) |
0 |
|
65% |
|
| Wang Xiaodong |
Chair, Scientific Advisory Brd |
– • – |
2022-09-06 |
4 |
GD |
$0.00 |
$0 |
D/D |
33,410 |
5,629,556 |
|
- |
|
| Yi Qingqing |
Director |
– • – |
2022-08-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(7,800) |
16,692 |
|
- |
|
527 Records found
|
|
Page 2 of 22 |
|
|
2.59 (1.65%) 
